This review highlights that hypertrophic cardiomyopathy in infants, children, and adolescents presents with wide clinical variability, sarcomeric genetic mutations, and sudden cardiac death risk.
This review summarizes the clinical presentation and characteristics of hypertrophic cardiomyopathy in infants, children, and adolescents.
Hypertrophic cardiomyopathy (HCM) is characterized by inappropriate left ventricular hypertrophy (LVH) in the setting of a nondilated left ventricle. HCM is often associated with asymmetric LVH, a family history of HCM, sarcomeric genetic mutations, and an increased risk of sudden cardiac death. There is a wide clinical variability in HCM presenting during childhood and a relative lack of data on the pediatric population. This review will cover HCM presenting in infancy, childhood, and adolescence.
Shiraz A. Maskatia (Sun,) conducted a review in Hypertrophic cardiomyopathy. This review highlights that hypertrophic cardiomyopathy in infants, children, and adolescents presents with wide clinical variability, sarcomeric genetic mutations, and sudden cardiac death risk.